Huang Shenlin, Li Ronghua, Connolly Peter J, Xu Guozhang, Gaul Michael D, Emanuel Stuart L, Lamontagne Kenneth R, Greenberger Lee M
Johnson and Johnson Pharmaceutical Research and Development, L.L.C, 1000 Route 202, Raritan, NJ 08869, USA.
Bioorg Med Chem Lett. 2006 Dec 1;16(23):6063-6. doi: 10.1016/j.bmcl.2006.08.107. Epub 2006 Sep 18.
A novel 4-aminopyrimidine-5-carboxaldehyde oxime scaffold with inhibitory activity against VEGFR-2 kinase has been identified. With a 4-fluoro-2-methylindol-5-yloxy group at the 6-position and alkyl groups as the oxime side chains, many analogues showed good potency for VEGFR-2. This series also exhibited antiproliferative activity against cancer cells, causing cell accumulation at the G2/M phase of the cell cycle and preventing cells from entering mitosis. Described here are the chemistry, structure-activity relationships (SAR), and biological testing for this series.
已鉴定出一种对VEGFR-2激酶具有抑制活性的新型4-氨基嘧啶-5-甲醛肟支架。在6位带有4-氟-2-甲基吲哚-5-氧基且肟侧链为烷基,许多类似物对VEGFR-2显示出良好的活性。该系列还表现出对癌细胞的抗增殖活性,导致细胞在细胞周期的G2/M期积累并阻止细胞进入有丝分裂。本文介绍了该系列的化学、构效关系(SAR)和生物学测试。